Works by Horak, Ivan D.


Results: 14
    1
    2
    3
    4
    5

    Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype.

    Published in:
    Science Translational Medicine, 2020, v. 12, n. 555, p. 1, doi. 10.1126/scitranslmed.aax8313
    By:
    • Lupo, Barbara;
    • Sassi, Francesco;
    • Pinnelli, Marika;
    • Galimi, Francesco;
    • Zanella, Eugenia R.;
    • Vurchio, Valentina;
    • Migliardi, Giorgia;
    • Gagliardi, Paolo Armando;
    • Puliafito, Alberto;
    • Manganaro, Daria;
    • Luraghi, Paolo;
    • Kragh, Michael;
    • Pedersen, Mikkel W.;
    • Horak, Ivan D.;
    • Boccaccio, Carla;
    • Medico, Enzo;
    • Primo, Luca;
    • Nichol, Daniel;
    • Spiteri, Inmaculada;
    • Heide, Timon
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14

    First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
    By:
    • Berlin, Jordan;
    • Tolcher, Anthony W.;
    • Ding, Cliff;
    • Whisenant, Jennifer G.;
    • Horak, Ivan D.;
    • Wood, Debra L.;
    • Nadler, Paul I.;
    • Hansen, Ulla Holm;
    • Lantto, Johan;
    • Skartved, Niels Jørgen Ø.;
    • Pedersen, Mikkel W.;
    • Patnaik, Amita
    Publication type:
    Article